Advanced Hepatocellular Carcinoma (HCC)

Oncology
3
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

CT
1 program
1
AK105 InjectionPhase 31 trial
Active Trials
NCT04344158Active Not RecruitingEst. Dec 2026
Astellas
AstellasChina - Shenyang
1 program
1
OSI-906Phase 21 trial
Active Trials
NCT01101906Terminated23Est. Dec 2011
Zai Lab
Zai LabCA - South SF
1 program
1
MGD013 monotherapyPhase 1/21 trial
Active Trials
NCT04212221Terminated89Est. Apr 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Chia Tai TianQing Pharmaceutical GroupAK105 Injection
AstellasOSI-906
Zai LabMGD013 monotherapy

Clinical Trials (3)

Total enrollment: 112 patients across 3 trials

A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)

Start: Aug 2020Est. completion: Dec 2026
Phase 3Active Not Recruiting

A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC

Start: Jan 2011Est. completion: Dec 201123 patients
Phase 2Terminated
NCT04212221Zai LabMGD013 monotherapy

MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients

Start: Apr 2020Est. completion: Apr 202289 patients
Phase 1/2Terminated

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space